ABpres Eye Drop

Brand Name: ABpres
Generic: Brimonidine Tartrate + Timolol Maleate
Weight: 0.2%+0.5%
Type: Eye Drop
Therapeutic Class: Drugs for miotics and glaucoma
Manufacturer: Navana Pharmaceuticals Ltd.
Price: 154.00
Last Updated: 2020-11-22 18:15:00

ABpres Eye Drop Uses

ABpres Eye Drop contains Brimonidine Tartrate + Timolol Maleate. ABpres uses:

Brimonidine Tartrate + Timolol Maleate is indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.

ABpres Eye Drop Doses

ABpres Eye Drop contains Brimonidine Tartrate + Timolol Maleate 0.2%+0.5%. ABpres doses:

The recommended dose is one drop of this eye drops in the affected eye(s) twice daily approximately 12 hours apart.

If more than one topical ophthalmic product is to be used, other eye drops should be instilled at least 5 minutes apart.

Safety and effectiveness in children below the age of 2 years have not been established.


Side Effects

The most frequent reactions of this combination are allergic conjunctivitis, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, ocular burning, blepharitis, corneal erosion, epiphora, eye dryness, eye pain, eyelid edema, eyelid pruritus, headache, hypertension, superficial punctate keratitis, and visual disturbance.


Brimonidine Tartrate + Timolol Maleate is a combination preparation of selective alpha-2 adrenergic receptor agonist, brimonidine and a non-selective beta-adrenergic receptor inhibitor, timolol. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action. Brimonidine lowers IOP by reducing aqueous humor production and increasing uveoscleral outflow. Timolol also lowers IOP by reducing aqueous humor production.

ABpres Precaution

Like other topically applied ophthalmic agents, it may be absorbed systemically. Due to the presence of Timolol, the same types of cardiovascular and pulmonary adverse reactions as seen with systemic beta-blockers may occur. Cautions should be exercised in treating patients with severe or unstable and uncontrolled cardiovascular or pulmonary diseases.


Specific drug interaction studies on this ophthalmic preparation have not been established

Pregnancy Lactation use

Pregnancy: Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. It should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.

Lactation: Timolol has been detected in human milk following oral and ophthalmic drug administration. It is not known whether brimonidine passes into human breast milk. However, it has been shown to pass into the milk of nursing animals. Because of the potential for serious adverse reactions from this combination in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.


Contraindicated in patients with hypersensitivity to any component of this medication, in patients receiving monoamine oxidase (MAO) inhibitor therapy, bronchospasm, bronchial asthma or severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block, cardiac failure or cardiogenic shock.

Special Warning

Safety and effectiveness in children below the age of 2 years have not been established.

Acute Overdose

No information is available on overdosage with this drops in humans.

Interaction with other Medicine

Monoamine oxidase inhibitors may result in increased hypotension. Antihypertensives/cardiac glycosides may lower blood pressure. Concomitant use with systemic beta-blockers may potentiate systemic beta-blockade. Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. Catecholamine-depleting drugs may have additive effects and produce hypotension and/or marked bradycardia. Use with CNS depressants may result in an additive or potentiating effect. CYP2D6 inhibitors may potentiate systemic beta-blockade.

Tricyclic antidepressants may potentially blunt the hypotensive effect of systemic clonidine.

Storage Condition

Store in a cool & dry place, protected from light

Keep out of reach of children

Do not use more than 4 weeks after opening

ABpres Eye Drop price in Bangladesh 154.00